



## Vistagen to Present at Stifel 2024 Virtual CNS Days

March 11, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 11, 2024-- Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024.

### Stifel 2024 Virtual CNS Days

- Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 20 at 12:00 p.m. Eastern Time.

A webcast will be accessible through the “[Events](#)” page in the “Investors” section of the Company’s website at [www.Vistagen.com](http://www.Vistagen.com). Investors interested in arranging a one-on-one meeting during the conference should contact their Stifel representative.

### About Vistagen

Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to inhibit, but not block, NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at [www.Vistagen.com](http://www.Vistagen.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20240311902490/en/>

#### Investors:

Mark A. McPartland  
(650) 577-3606  
[markmcp@vistagen.com](mailto:markmcp@vistagen.com)

#### Media:

Caren Scannell  
(650) 577-3601  
[cscannell@vistagen.com](mailto:cscannell@vistagen.com)

Source: Vistagen